Help
RSS
API
Feed
Maltego
Contact
Domain > www.enspryng.com
×
More information on this domain is in
AlienVault OTX
Is this malicious?
Yes
No
DNS Resolutions
Date
IP Address
2019-09-22
52.9.196.166
(
ClassC
)
2024-10-24
104.18.31.32
(
ClassC
)
2025-01-14
104.18.30.32
(
ClassC
)
Port 80
HTTP/1.1 301 Moved PermanentlyDate: Thu, 15 Aug 2024 02:48:59 GMTContent-Type: text/htmlTransfer-Encoding: chunkedConnection: keep-aliveLocation: https://www.enspryng.com:443/CF-Cache-Status: DYNAMICS html>head>title>301 Moved Permanently/title>/head>body>center>h1>301 Moved Permanently/h1>/center>/body>/html>
Port 443
HTTP/1.1 200 OKDate: Thu, 15 Aug 2024 02:48:59 GMTContent-Type: text/html; charsetUTF-8Transfer-Encoding: chunkedConnection: keep-alivevary: Accept-EncodingCF-Cache-Status: DYNAMICSet-Cookie: __cf_bmy !DOCTYPE HTML>html langen-US> head> meta charsetUTF-8/> title>ENSPRYNG® (satralizumab) | Neuromyelitis Optica Spectrum Disorder (NMOSD) Treatment/title> meta namedescription contentLearn about ENSPRYNG® (satralizumab), a self-administered, monthly treatment for Neuromyelitis Optica Spectrum Disorder (NMOSD). See full safety for more information./> meta nametemplate contentflexible-page/> meta nameviewport contentwidthdevice-width, initial-scale1/> link relcanonical hrefhttps://www.enspryng.com//> meta propertyog:site_name contentenspryng/> meta propertyog:type contentwebsite/> meta propertyog:locale contenten_US/> meta propertyog:title contentENSPRYNG® (satralizumab) | Neuromyelitis Optica Spectrum Disorder (NMOSD) Treatment/> meta propertyog:description contentLearn about ENSPRYNG® (satralizumab), a self-administered, monthly treatment for Neuromyelitis Optica Spectrum Disorder (NMOSD). See full safety for more information./> meta propertyog:url contenthttps://www.enspryng.com//> meta propertyog:image contenthttps://www.enspryng.com/content/dam/gene/enspryng/logos/enspryng-satralizumab-mwge-full-color-logo-rball.genecoreimg.1200.svg/> meta propertyog:image:type contentimage/svg+xml/> meta propertyog:image:width content134/> meta propertyog:image:height content102/> meta propertyog:image:alt contentENSPRYNG® (satralizumab) logo/> meta nametwitter:card contentsummary_large_image/> link relicon typeimage/x-icon href/content/dam/gene/enspryng/logos/favicon.ico/> link relshortcut icon typeimage/x-icon href/content/dam/gene/enspryng/logos/favicon.ico/> link hrefhttps://fonts.googleapis.com/css2?familyOpen+Sans:ital,wght@0,400;0,700;1,400;1,700&displayswap relstylesheet/> script typetext/plain classoptanon-category-C0002> window.NREUM||(NREUM{}),__nr_requirefunction(t,n,e){function r(e){if(!ne){var one{exports:{}};te0.call(o.exports,function(n){var ote1n;return r(o||n)},o,o.exports)}return ne.exports}if(func
View on OTX
|
View on ThreatMiner
Please enable JavaScript to view the
comments powered by Disqus.
Data with thanks to
AlienVault OTX
,
VirusTotal
,
Malwr
and
others
. [
Sitemap
]